All News

In patients with high-grade T1 disease, high-grade EFS was 100% and 3 months and at 6 months and 87.5% at 9 months.

Following treatment with SYNC-T, all bone metastases had resolved in 7 of the 13 patients.

The overall CR rate was 83.7% (95% CI, 70.3-92.7).

Forty-one of the 85 patients experienced disease persistence, progression, or recurrence.

CR at any time was 92% (23/25 patients), 84% (21/25) at 3 months, 87% (20/23) at 6 months, and 85% (17/20) at 9 months.

The data come just days after the FDA approved IsoPSA to aid in the diagnosis of high-grade prostate cancer.

For micro-ultrasound compared with true cancer status, estimated sensitivity was 0.8000.

The HCPs and AHCPs described insertion and removal of the system to be “straightforward” and done in less than 5 minutes.

At a median follow-up of 25.8 months, the CR rate at any time was 75.5%.

The investigators reported that new onset of CNS-related conditions was lower in patients in the apalutamide cohort at 12 months and 24 months post index.

The approval is supported by 12-month data from the prospective VAPOR 2 trial.

At a median follow-up of 18.8 months, the confirmed ORR was 31%.

"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.

A recap of the FDA submissions and regulatory decisions in urology from November 2025.

The test is intended to aid in the decision for prostate biopsy in men aged 50 years or older who present with elevated PSA levels.

In this episode, Farnoosh Nik-Ahd, MD, joins host Adam Weiner, MD, to discuss emerging guidance on prostate cancer screening in transgender women.

"Based on the code description, we recommend basing the code selection on the documentation and the effort required to complete the service, and not the number of foreign bodies removed from the bladder," write Jonathan Rubenstein, MD, and Mark Painter.

"Site neutrality is a pivotal issue for all independent practices, and really, it's a pivotal issue for all Americans because it affects both the global cost of care as well as the acceleration and the cost of care," says Mara R. Holton, MD.

According to the authors, the optimal duration of treatment could be tied to individual patient factors such as cancer risk.

The authors suggested that a greater treatment effect may be observed with a more antigenic vaccine.

AVZO-103 is a Nectin-4/TROP2 biospecific antibody-drug conjugate for adult patients with urothelial carcinoma whose tumors have progressed on enfortumab vedotin.

John Lam, MD, outlines the legislative efforts underway, the impact of prior authorization on patient care, and the role organized medicine can play in pushing for meaningful change.

The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.

Notably, 81% of patients said that they were interested in trying new or different treatment options.

In September 2024, the FDA granted an Orphan Drug Designation and a Rare Pediatric Disease Designation to YOLT-203 for PH1.

The clearance supports new ultrasound imaging and workflow enhancements to the Focal One i, which was launched earlier this year.

The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.

The subcutaneous formulation of pembrolizumab also received FDA approval in September 2025.